Cargando…

SEPROGADIC – serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy

Gastric cancer (GC) patients usually receive surgical treatment. Postoperative therapeutic options such as anticancer adjuvant therapies (AT) based on prognostic prediction models would provide patient-specific treatment to decrease postsurgical morbidity and mortality rates. Relevant prognostic fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Hee-Sung, Sohn, Tae Sung, Kim, Mi Jeong, Cho, Byoung Kyu, Kim, Su Mi, Kim, Seung Tae, Yi, Eugene C., Lee, Cheolju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237900/
https://www.ncbi.nlm.nih.gov/pubmed/30442939
http://dx.doi.org/10.1038/s41598-018-34858-x
_version_ 1783371266991849472
author Ahn, Hee-Sung
Sohn, Tae Sung
Kim, Mi Jeong
Cho, Byoung Kyu
Kim, Su Mi
Kim, Seung Tae
Yi, Eugene C.
Lee, Cheolju
author_facet Ahn, Hee-Sung
Sohn, Tae Sung
Kim, Mi Jeong
Cho, Byoung Kyu
Kim, Su Mi
Kim, Seung Tae
Yi, Eugene C.
Lee, Cheolju
author_sort Ahn, Hee-Sung
collection PubMed
description Gastric cancer (GC) patients usually receive surgical treatment. Postoperative therapeutic options such as anticancer adjuvant therapies (AT) based on prognostic prediction models would provide patient-specific treatment to decrease postsurgical morbidity and mortality rates. Relevant prognostic factors in resected GC patient’s serum may improve therapeutic measures in a non-invasive manner. In order to develop a GC prognostic model, we designed a retrospective study. In this study, serum samples were collected from 227 patients at a 4-week recovery period after D2 lymph node dissection, and 103 cancer-related serum proteins were analyzed by multiple reaction monitoring mass spectrometry. Using the quantitative values of the serum proteins, we developed SEPROGADIC (SErum PROtein-based GAstric cancer preDICtor) prognostic model consisting of 6 to 14 serum proteins depending on detailed purposes of the model, prognosis prediction and proper AT selection. SEPROGADIC could clearly classify patients with good or bad prognosis at each TNM stage (1b, 2, 3 and 4) and identify a patient subgroup who would benefit from CCRT (combined chemoradiation therapy) rather than CTX (chemotherapy), or vice versa. Our study demonstrated that serum proteins could serve as prognostic factors along with clinical stage information in patients with resected gastric cancer, thus allowing patient-tailored postsurgical treatment.
format Online
Article
Text
id pubmed-6237900
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62379002018-11-23 SEPROGADIC – serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy Ahn, Hee-Sung Sohn, Tae Sung Kim, Mi Jeong Cho, Byoung Kyu Kim, Su Mi Kim, Seung Tae Yi, Eugene C. Lee, Cheolju Sci Rep Article Gastric cancer (GC) patients usually receive surgical treatment. Postoperative therapeutic options such as anticancer adjuvant therapies (AT) based on prognostic prediction models would provide patient-specific treatment to decrease postsurgical morbidity and mortality rates. Relevant prognostic factors in resected GC patient’s serum may improve therapeutic measures in a non-invasive manner. In order to develop a GC prognostic model, we designed a retrospective study. In this study, serum samples were collected from 227 patients at a 4-week recovery period after D2 lymph node dissection, and 103 cancer-related serum proteins were analyzed by multiple reaction monitoring mass spectrometry. Using the quantitative values of the serum proteins, we developed SEPROGADIC (SErum PROtein-based GAstric cancer preDICtor) prognostic model consisting of 6 to 14 serum proteins depending on detailed purposes of the model, prognosis prediction and proper AT selection. SEPROGADIC could clearly classify patients with good or bad prognosis at each TNM stage (1b, 2, 3 and 4) and identify a patient subgroup who would benefit from CCRT (combined chemoradiation therapy) rather than CTX (chemotherapy), or vice versa. Our study demonstrated that serum proteins could serve as prognostic factors along with clinical stage information in patients with resected gastric cancer, thus allowing patient-tailored postsurgical treatment. Nature Publishing Group UK 2018-11-15 /pmc/articles/PMC6237900/ /pubmed/30442939 http://dx.doi.org/10.1038/s41598-018-34858-x Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Ahn, Hee-Sung
Sohn, Tae Sung
Kim, Mi Jeong
Cho, Byoung Kyu
Kim, Su Mi
Kim, Seung Tae
Yi, Eugene C.
Lee, Cheolju
SEPROGADIC – serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy
title SEPROGADIC – serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy
title_full SEPROGADIC – serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy
title_fullStr SEPROGADIC – serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy
title_full_unstemmed SEPROGADIC – serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy
title_short SEPROGADIC – serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy
title_sort seprogadic – serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237900/
https://www.ncbi.nlm.nih.gov/pubmed/30442939
http://dx.doi.org/10.1038/s41598-018-34858-x
work_keys_str_mv AT ahnheesung seprogadicserumproteinbasedgastriccancerpredictionmodelforprognosisandselectionofproperadjuvanttherapy
AT sohntaesung seprogadicserumproteinbasedgastriccancerpredictionmodelforprognosisandselectionofproperadjuvanttherapy
AT kimmijeong seprogadicserumproteinbasedgastriccancerpredictionmodelforprognosisandselectionofproperadjuvanttherapy
AT chobyoungkyu seprogadicserumproteinbasedgastriccancerpredictionmodelforprognosisandselectionofproperadjuvanttherapy
AT kimsumi seprogadicserumproteinbasedgastriccancerpredictionmodelforprognosisandselectionofproperadjuvanttherapy
AT kimseungtae seprogadicserumproteinbasedgastriccancerpredictionmodelforprognosisandselectionofproperadjuvanttherapy
AT yieugenec seprogadicserumproteinbasedgastriccancerpredictionmodelforprognosisandselectionofproperadjuvanttherapy
AT leecheolju seprogadicserumproteinbasedgastriccancerpredictionmodelforprognosisandselectionofproperadjuvanttherapy